Whether these hormonal influences within the RAS modulate performance and security of ACE-I or ARBs, have not been established . of reports in women in six out of ten groups of antihypertensive medicines, and this may potentially become linked to dose exposure. Aldosterone antagonists was the only group with a higher prevalence of ADE-reports in males with a similar dose exposure between men and women. Electronic supplementary material The online version of this article (10.1007/s00228-018-2480-y) contains supplementary material, which is available to authorized users. Keywords: Antihypertensive treatment, Ladies, Men, Adverse drug events, Sex-differences Intro Studies have shown that women possess a 50C70% higher risk of suffering from adverse drug reactions (ADRs) compared to men, and furthermore patients admitted to hospital with an ADR are in 60% of the instances ladies [1, 2]. You will find variations in pharmacokinetics between men and women, making women in general more susceptible to dose-dependent ADRs . Several factors influence the bioavailability and distribution of medicines, such as the percentage of slim to fat cells, circulating plasma volume, and the amount of plasma proteins binding the drug . Normally, the body composition in ladies includes higher percentage of body fat and a lower body mass [3, 5]; as a result, lipid soluble medicines with a longer half-life and water soluble medicines may yield higher exposure in ladies. Many medicines are metabolized by enzymes of the CYP system. Sex variations have been demonstrated concerning CYP1A2, CYP2D6, CYP2E1, and CYP3A4  but studies on the medical impact of these variations are scarce . Renal clearance is usually higher in males than in ladies . Ladies may respond to cardiovascular medication in a different way than males , and sex variations in pharmacodynamic reactions may include both improved and decreased effects as well as adverse effects in ladies compared to males. It is possible that these variations, at least in part, may relate to exposure. For example, PTP1B-IN-8 drug-induced Torsade de Pointes ventricular tachycardia, electrolyte abnormalities with diuretics, dry cough with angiotensin-converting enzyme inhibitors (ACE-I) , higher incidence of peripheral edema, and better response of amlodipine  are more common in ladies. Studies on ambulatory medical populations display ladies generally reporting more symptoms than males [10, 11]. Ladies generally statement more bodily stress and more frequent somatic symptoms than males ; this could even lead to variations in the reporting of adverse drug events (ADEs). However, in a regional pharmacovigilance center in France, there was no sex difference in the incidence of reporting PTP1B-IN-8 of ADRs overall . Furthermore, no sex difference was seen in suspected ADRs to ACE inhibitors and ARBs in spontaneous reports in the Campania region, Italy . Spontaneous reporting of ADEs is an important tool in obtaining better knowledge about sex variations in ADEs, in addition to the info from your medical tests carried out before the drug has been launched on the market. Therefore, we carried out a study to explore sex variations concerning reported ADEs from your ten most commonly prescribed antihypertensive medicines in Sweden, using the Swedish pharmacovigilance INHBB database SWEDIS and the Swedish Prescribed Drug Register (SPDR). Methods This was a cross sectional study combining data on reported ADEs from SWEDIS and data on dispensed medicines from your SPDR. An ADR may be defined as harm directly caused by the drug at normal doses and during normal use compared to an ADE which has a wider definition, which includes ADRs, overdoses, dose reductions, and discontinuations of drug therapy . The lack of information about the specific reactions in pharmacovigilance databases made us chose the wider definition, ADEs, when referring to the reports. Data on ADEs was extracted from SWEDIS, which was founded in 1965 and contained more than 130,000 spontaneous ADE-reports at the end of December 2012. In Sweden, at the time of the study period, physicians, dentists, and nurses were supposed PTP1B-IN-8 to statement severe ADEs; ADEs not described in the Summary of Product Characteristics (SPC); ADEs related to the use of fresh medicines (?2?years after authorization) except those already labeled as common in the SPC; and ADEs that seem to be increasing in incidence, to any of Swedens six regional pharmacovigilance centers. Specially qualified nurses and medical pharmacologists examined the.